Ipamorelin vs Tesamorelin
Ipamorelin and tesamorelin act at different levels of the GH axis. A US research comparison of receptor targets, model systems and published data.
Ipamorelin and tesamorelin act at different levels of the GH axis. A US research comparison of receptor targets, model systems and published data.
GLP-1 receptor agonist pharmacology for US laboratories: binding, bias, internalization, species-specific half-lives and multi-agonist mechanisms.
Ships from the USA describes the last leg. Where a research peptide’s impurity profile is actually set, and where the only number on the COA comes from.
Reduction is a reagent problem. Why the identity and content of a research peptide is an animal-welfare variable, not just a quality-control one.
A particle count is a method, not a number. USP says its own two methods are not interchangeable, and the published gap runs to two orders of magnitude.
Below about 0.2 micron, microbial ingress stops. Above it, it does not. What the leak-rate literature says about the one vial attribute no COA reports.
Purity is a snapshot; degradation rate is a sequence property. What deamidation, racemization, oxidation and hydrolysis do, and why a COA cannot see it.
A certificate ends at the vial. Below about 1 micromolar most of a cationic peptide can end up on the tube wall. What the published recovery data says.
ICH Q1B defines a measurable photostability test. No research peptide certificate reports one. What light actually does to a lyophilized vial, and when.
What an ICH accelerated stability study measures, what it is not allowed to predict, and why no research peptide certificate carries a shelf life.